Background

Acute exacerbation in chronic obstructive pulmonary disease (AECOPD) is the most common reason for hospital admission among patients with chronic obstructive pulmonary disease (COPD) [1]. These events result in higher mortality and lower quality of life [2]. The estimated mortality rate within 90 days after hospitalization for AECOPD is approximately 3.6% (1.8–20.4%) while mortality rate during the first 2 years after admission for AECOPD is approximately 31.0% (18.8–45.4%) [3]. The estimated 30-day and 12-month readmission-rate after AECOPD hospitalization is approximately 19.2% [4] and 42.3% [5], respectively. Readmission following an AECOPD has a negative effect on physical performance by lowering exercise capacity, muscle strength and physical activity level, which patients may never fully recover from [6, 7]. Patients with frequent exacerbations may be prone to a more rapid decline in activities of daily living (ADL) and functional capacity, which is associated with reductions health-related quality of life (HRQoL) [6]. Repeated exacerbations may cause a vicious circle as physical inactivity and low exercise capacity are related to a higher risk of hospital readmission, regardless of the COPD severity [8].

Pulmonary rehabilitation (PR) has been suggested in AECOPD because of its known beneficial effects on exercise capacity, HRQoL and symptom burden in stable patients [9, 10]. It should be noted that the evidence in favor of PR in stable COPD is based on studies investigating supervised PR programs including exercise training for 6–12 weeks [11, 12], although at long-term follow-up, adherence to exercise training is low and effects are not maintained [13]. Likewise, studies have shown that early PR, initiated at the beginning of exacerbation treatment or within 3 weeks of initiation of exacerbation treatment, improves exercise capacity and HRQoL along with reductions in hospital readmissions [14] and mortality [15] compared with no PR. Based on evidence from randomized controlled trials (RCT), NICE guidelines from 2011 recommended the use of early PR in patients hospitalized with COPD exacerbations [16]. Yet, recent concerns have been raised about PR not being safe in AECOPD when initiated during the hospital admission [17]. Based on this new evidence, the 2017 guideline from the European Respiratory Society (ERS) and American Thoracic Society (ATS) recommend that PR is not initiated during hospitalization in patients with COPD related exacerbations, but is delayed until after hospital discharge (within 3 weeks) [18]. However, the ERS/ATS recommendation was based on both supervised and unsupervised PR programs, and interestingly, the potentially negative effects of early PR were mainly driven by studies providing unsupervised PR.

Therefore, our aim was to investigate the effect of a supervised early PR program, initiated during or within 4 weeks, in patients hospitalized with a COPD exacerbation compared with usual care. Our primary outcome was mortality at the end of PR and at the longest follow-up. Secondary outcomes were hospital readmission, days in hospital, HRQoL and exercise capacity. We followed the guidelines of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group [19] in order to support clinical decision making in a national Danish setting where only supervised PR programs take place.

Methods

Protocol and registration

This review was among a series of reviews performed for a guideline developed by the Danish Health Authority. The population, intervention, control intervention (comparison) as well as critical and important outcomes (PICO) [20] were determined by the working-group members prior to our literature search. The methods and review process are a standardized part of the guideline development process within the Danish Health Authority. The methods handbook (in Danish) as well as the full guideline and more detail regarding the PICO can be accessed at www.sst.dk, the full guideline can also be found on https://app.magicapp.org/app#/guideline/2551.

Eligibility criteria

We considered studies eligible if they compared the effect of early supervised PR initiated during admission or within 4 weeks of hospital discharge (intervention) with no early pulmonary rehabilitation/usual care (comparison) in patients admitted and/or having been admitted to hospital with exacerbations of COPD (population). The PR was defined by a main component of supervised exercise training but could contain education, smoking cessation, nutritional support, management in activities of daily living (ADL) and physio-social support.

Studies providing inpatient pulmonary rehabilitation with exercise training was included if rehabilitation were continued after hospital discharge and/or a comprehensive rehabilitation program could be documented. Studies were excluded if they were not randomized or did not cover the predefined PICO. Our pre-specified outcomes were evaluated immediately after the end of intervention and at the longest follow up. Our primary outcome was mortality while secondary outcomes included number of days in hospital, number of COPD related hospital readmissions, health related quality of life (HRQoL), exercise capacity (walking tests), activities of daily living (ADL), falls and dropout.

Information sources and search strategy

A research librarian and search specialist performed the systematic literature search including the following databases: Medline, Embase, Physiotherapy Evidence Database (PEDRO), CINAHL, G-I-N international, NICE, National Guideline Clearinghouse, Surgical Implant Generation Network, Cochrane Library and OTseeker. The full search strategy is presented in Additional file 1.

This review is an update of a previous review. First, a comprehensive search for COPD rehabilitation guidelines and systematic reviews was conducted in July 2013, yielding a total of 2412 records. In November 2013, a second and more specific search (Medline, Embase and PEDRO) for RCTs was performed, in which 876 additional records were identified. An updated search for guidelines and systematic reviews was conducted in July 2017, covering the period from July 2013 to July 2017, where we identified 460 additional records. The search for primary studies was updated in October 2017, covering the period from December 2013 to October 2017. The search resulted in 1187 additional records (Fig. 1). All records were screened for relevant titles or abstracts, while reference lists of included studies were assessed for further eligible literature.

Fig. 1
figure 1

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of the article selection processes

Study selection

Clinical guidelines identified in the first search were evaluated with the Appraisal of Guidelines for Research and Evaluation instrument version II (AGREE II) by two independent authors and disagreement was resolved through consensus (see Additional file 2). Likewise, systematic reviews were assessed with A Measurement Tool to Asses Systematic Reviews (AMSTAR) by three authors and disagreement was resolved through consensus (see Additional file 3). Based on these assessments we decided to include one clinical guideline [21] and two systematic reviews [14, 15]. From the second search, two authors independently evaluated the full text of all potentially eligible studies and decided whether to include or exclude each study based on the prespecified criteria.

Data analysis and risk of bias

Data on participants, study design, interventions and outcomes were extracted from the full-text reports of the included studies by two independent authors, using Covidence (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org). Disagreement was resolved through consensus. Each included study was assessed using the Cochrane risk of bias tool [22]. Two independent authors performed the risk of bias assessment, and disagreement was resolved through discussion and consensus (see Additional file 4).

We used mean difference (MD) to calculate effect estimates for continuous outcomes if the same scale was used for a particular outcome. When pooling continuous outcome data from different scales a standardized mean difference (SMD) was calculated. Rate ratio and relative risk (RR) was used to calculate effects for dichotomous outcomes. Random-effects meta-analyses were performed as we expected variation in population, duration of intervention, and types of training between the included studies. Review Manager 5.3 software [23] was used for the statistical analyses and to produce forest plots. Heterogeneity in the effect estimate was determined using the I-square (I2) statistic and values below 40% indicated low heterogeneity [24].

The quality of evidence for each outcome was assessed across the included studies as proposed by the GRADE Working Group [25]. A draft of the grading for each outcome using the GRADE criteria (i.e., risk of bias, inconsistency, indirectness, imprecision, and publication bias) was presented to the working group and the final grading was reached through discussion and consensus. The full guideline was then submitted to peer review and public hearing. For details on the hearing see www.sst.dk (in Danish).

Assessment of PR extensiveness

We assessed the extensiveness of the PR program in the included trials by following the statements and guidelines from BTS [26], ERS/ATS [10]), and as described in Puhan et al. [14] (see Additional file 5).

Results

Study selection

We identified 13 eligible primary RCTs for our analysis. These included a total of 801 participants who were in the recovery phase of a recent COPD exacerbation. Excluding dropouts (167 participants), 634 participants were included in our analysis. Nine of the 13 studies were included in a systematic Cochrane review [14]. Figure 1 summarizes the flow diagram of the two selection processes.

Included studies

Table 1 shows the characteristics of the included studies. In three studies [27,28,29] patients initiated an inpatient PR program within 4 to 8 days of hospital admission. In one study [30] patients began PR as either in- or outpatients and all continued as outpatients, in eight studies [31,32,33,34,35,36,37,38] the outpatient program was initiated within one to four weeks after the inpatient exacerbation treatment and in one study [39] the outpatient rehabilitation was initiated after the “hospital at home” treatment of the exacerbation. In four studies [27, 29, 38, 39] the PR consisted of only supervised exercise training, whereas in the remaining nine studies [28, 30,31,32,33,34,35,36,37] PR consisted of supervised exercise training and education, smoking cessation, nutritional support, management in activities of daily living (ADL) and physio-social support. Duration of the different PR programs was ten days to six months, with training frequencies ranging from two to seven times a week, and exercise durations of 30–90 min per session. Table S1 in the Additional file 5 shows the extensiveness of the PR programs in the included trials. The participants followed an extensive PR program in ten of the included trials [27,28,29,30,31, 33,34,35,36, 38]. In the remaining three studies, the extensiveness of the PR was deemed as moderate [39], slightly extensive [37], and undescribed [32]. The control group received usual care consisting of optimal medical treatment. There were no reported differences in baseline characteristics of patients between groups in all of the included studies.

Table 1 Characteristics of the included studies

Risk of bias within studies

Figures 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 and Additional file 4 shows risk of bias of the included studies. In nine studies [28, 29, 31, 32, 34,35,36,37,38] the allocation concealment was not described, while seven studies [27, 29, 31, 36,37,38,39] did not report the randomization process. Three studies [27, 34, 39] blinded the personnel, with only two of the studies [34, 39] blinding the outcome assessor. One study [27] was assessed as having a high risk of incomplete outcome data reporting due to a large dropout. Selective outcome reporting of outcome measures was detected in one study [34]. No other sources of bias were detected. Thus, the quality of evidence from all studies included was downgraded due to risk of bias (Table 2, Additional file 4).

Fig. 2
figure 2

The effect of supervised early PR versus usual care on mortality at the end of treatment.

Fig. 3
figure 3

The effect of supervised early PR versus usual care on mortality at the longest follow up

Fig. 4
figure 4

The effect of supervised early PR versus usual care on days in hospital at the end of treatment

Fig. 5
figure 5

The effect of supervised early PR versus usual care on COPD related hospital readmissions at the longest follow up

Fig. 6
figure 6

The effect of supervised early PR versus usual care on health-related quality of life at the end of treatment using the St. George’s Respiratory Questionnaire

Fig. 7
figure 7

The effect of supervised early PR versus usual care on health-related quality of life at the longest follow up using the St. George’s Respiratory Questionnaire

Fig. 8
figure 8

The effect of supervised early PR versus usual care on walking distance at the end of treatment using the 6-Minute Walking Test

Fig. 9
figure 9

The effect of supervised early PR versus usual care on walking distance at the end of treatment using the Shuttle Walking Test

Fig. 10
figure 10

The effect of supervised early PR versus usual care on walking distance at the longest follow up using the 6-Minute Walking Test

Fig. 11
figure 11

The effect of supervised early PR versus usual care on dropout at the end of treatment

Fig. 12
figure 12

The effect of supervised early PR versus usual care on dropout at the longest follow up

Table 2 GRADE Evidence Profile

Effect of the intervention

We preformed meta-analyses in ten of our predefined outcomes. Subgroup analyses were undertaken in order to reveal differences between PR initiated during admission or within one week after discharge and PR initiated between one and four weeks after discharge from hospital. For an overview of all the outcomes, our confidence in the estimates and our interpretations see Table 2 GRADE Evidence profile.

Mortality

Total mortality after end of treatment was reported in four of the included studies, including 319 randomized participants (early PR: N = 163; usual care: N = 156) [29, 32, 33, 37]. A total of 18 events were reported in the early PR group, whereas 27 events were reported in the usual care group. We found a statistically significant reduction in mortality favoring PR (RR = 0.58 (95% CI: [0.35 to 0.98])), with low heterogeneity (Fig. 2). The quality of evidence was downgraded due to unclear sequence generation, allocation concealment and blinding together with selective outcome reporting (Table 2).

Total mortality at longest follow up was reported in three of the included studies, including 127 participants (early PR: N = 64; usual care: N = 63) [26, 33, 34]. Two events were reported in the early PR groups while four events were reported in the usual care group. We found no statistical significant difference between groups (RR = 0.55 (95% CI: [0.12 to 2.57])). Subgroup analysis showed no difference in effect between trials with PR initiated during admission and after discharge (P = 0.70) (Fig. 3). Our confidence in the effect estimate was downgraded due to unclear sequence generation and allocation concealment together with lack of precision, incomplete outcome data and selective reporting (Table 2).

Days in hospital

One study investigated the effect of early PR on the number of days in hospital after the end of treatment and stated that early PR led to a statistically reduction of 4.27 days (95% CI: [− 6.85 to − 1.69]) in the number of days in hospitals (Fig. 4). Accordingly, our confidence in the effect estimate was downgraded due to inclusion of only one study (Table 2).

COPD related hospital readmissions

Six studies provided data from 365 participants on the number of COPD related hospital readmissions 3–12 months from baseline [27, 28, 33, 35, 36, 38]. The pooled effect estimate showed a decrease in the number of COPD related hospital readmissions favoring the early PR (RR = 0.47 (95% CI: [0.29 to 0.75])). Low heterogeneity (I2 = 38%) was observed, and the subgroup analysis showed no difference in effect between trials with PR initiated during admission and after discharge (P = 0.93) (Fig. 5). The quality of evidence was downgraded due to unclear sequence generation and allocation concealment together with lack of blinding and incomplete outcome date (Table 2).

Health-related quality of life

The St. George’s Respiratory Questionnaire (SGRQ) (scale from 0 to 100, lower is better) were used across studies to assess HRQoL. Two studies were included and data from 86 participants were pooled in a meta-analysis evaluating HRQoL directly after end of early PR [31, 32] and showed a statistically and clinically significant improvement of 19.43 units on the SGRQ scale (95% CI: [− 29.09 to − 9.77]) in the early PR group compared with the usual care group (Fig. 6) with low heterogeneity. Our confidence in the effect estimate was downgraded due to unclear sequence generation, allocation concealment, blinding of assessors and incomplete outcome data (Table 2).

Four different studies provided data from 323 participants on the effect of early PR on HRQoL 3–12 months from baseline [33,34,35,36] and showed a statistically and clinically relevant improvement of 8.74 units on the SGRQ scale (95% CI: [− 12.02 to − 5.45]) in the early PR group compared with the usual care group (Fig. 7). Subgroup analysis showed no difference in effect between trials with PR initiated during admission and after discharge (P = 0.49). Unclear sequence generation, allocation concealment, blinding and selective outcome reporting led to downgrading of the confidence in our effect estimates (Table 2).

Walking distance

The walking distance (6-Minute Walking Test (6MWT) or Shuttle Walking Test (SWT)) after the end of treatment was investigated in eight studies [28, 29, 31, 32, 36,37,38,39]. Pooling the results (early PR: N = 139; usual care: N = 135) from five trials using 6MWT yielded a statistically significant mean difference in walking distance of 76.89 m, favoring early PR (95% CI: [21.34 to 132.45]) with high heterogeneity (Fig. 8). The subgroup analysis showed no difference in the effect between PR initiated during admission and after discharge (P = 1.00). However, we found a significant within-group effect of early PR after discharge (Fig. 8). The quality of evidence was downgraded due to unclear sequence generation, allocation concealment, blinding of assessors and incomplete data together with high risk of inconsistency (Table 2). Three trials (early PR: N = 50; usual care: N = 45) used the SWT to evaluate the walking distance after the end of treatment and showed a statistically significant mean difference in walking distance of 54.70 m, favoring early PR (95% CI: [30.83 to 78.57]). The subgroup analysis showed no difference in the effect between PR initiated during admission and after discharge (P = 0.40). However, we found a significant within-group effect of early PR during admission and after discharge (Fig. 9). The quality of evidence was downgraded due to unclear sequence generation, allocation concealment, blinding of assessors, incomplete outcome together with selective outcome reporting (Table 2).

Three different studies provided data from 217 participants on the effect of early PR on walking distance assessed by 6MWT at 3–12 months from baseline [27, 33, 34] and showed no statistically, but a clinically relevant difference (mean difference: 90.27 m; 95% CI: [− 69.53 to 250.08]) with high heterogeneity (Fig. 10). Subgroup analysis showed a statistically significant difference between groups in favor of early PR during admission (P < 0.01) (Fig. 10). Due to unclear sequence generation, allocation concealment, blinding of assessors, incomplete data and selective reporting together with high risk of inconsistency leading to high risk of imprecision the quality of evidence was downgraded (Table 2).

Drop-outs

The effect of early PR on the drop-out rate at the end of treatment was investigated in eight studies providing data from 440 randomized participants (early PR: N = 228; usual care: N = 212) [27, 28, 30, 34, 35, 37,38,39]. A total of 54 drop-outs were reported in the early PR group, whereas 46 drop-outs were reported in the usual care group, with no significant difference between groups (RR = 0.99 (95% CI: [0.71 to 1.39])) (Fig. 11). The subgroup analysis showed no difference in the effect between PR initiated during admission and after discharge (P = 0.37). Our confidence in the effect estimate was downgraded due to unclear sequence generation, allocation concealment, blinding of assessors and incomplete data outcome together with high risk of inconsistency (Table 2).

Three different studies provided data from 181 participants on the effect of early PR on drop-out at 3–18 months from baseline (early PR: N = 92; usual care: N = 89) [34, 36, 38]. A total of 20 drop-outs were reported in the early PR group, while 18 drop-outs were reported in the usual care group, with no difference between groups (RR = 1.05 (95% CI: [0.60 to 1.85])) (Fig. 12, Table 2). Subgroup analysis showed no difference in the effect between trials with PR initiated during admission and after discharge (P = 0.30; I2 = 6.5%) (Fig. 12).

None of the included studies reported results on the effect of early PR on ADL or the risk of falling.

Discussion

Summary of main findings

The present review summarized the evidence from 13 RCTs including 634 participants with an exacerbation of COPD and compared the use of early PR (N = 322) with usual care (N = 312). Subsequent meta-analysis showed that supervised early PR after acute exacerbation of COPD reduced mortality and number of days in hospital together with a reduction in COPD related hospital admissions and an improvement of HRQoL and exercise capacity (walking distance).

Mortality

We found that supervised early PR in patients with exacerbation of COPD reduced risk of mortality by ~ 42% compared with usual care. This finding was based on moderate quality of evidence due to methodological issues in the included studies and the relatively small numbers of participants. While similar conclusions have been reported in guidelines and systematic reviews in the past, results from a resent RCT by Greening et al. questioned the beneficial effects by reporting higher mortality in the early PR group [15,16,17]. In this study authors included patients with COPD related exacerbations during admission and instructed participants in the intervention group to be more physical active the next three months facilitated by technical devices [17]. In contrast, the majority of evidence favoring PR in stable COPD is based on supervised programs, and therefore we did not include Greening et al. in our review. However, to assess safety of early PR initiated during the hospital admission we performed a subgroup analysis showing no difference between groups rehabilitated during the admission and after discharge.

Results from this review differ from a previous review by Puhan et al. [14] who showed no statistically significant effect of early PR on mortality, but when the authors preformed a subgroup analysis, excluding results from Greening et al. [17], they did find a positive effect of early PR on mortality [14]. Moreover, the review by Puhan et al. [14] differs methodologically from the present review, as they included any inpatient and/or outpatient PR program with no criteria for the comprehensiveness or supervision of the rehabilitation program. We only included studies of supervised PR programs similar to what is offered to COPD patients in Denmark, which is based on the present large amount of evidence in favor of supervised PR in stable COPD. This might explain the lower heterogeneity and greater effects on mortality in the present review.

Hospital length of stay and readmissions

Moderate-quality evidence showed that supervised early PR significantly reduced the risk of COPD related hospital readmissions at the longest follow up with 53%. In addition, the number of days in hospital was reduced by an average of 4.27 days. Puhan et al. [14] have previously shown that PR significantly reduced the mean number of hospital admissions per participant from 1.6 to 0.9 during the year following after hospital admission for an acute exacerbation. Several explanations have been proposed for the substantial effect of PR on hospital readmission. The main reason is probably that hospitalization following an acute exacerbation of COPD leads to significant reductions in activity level [6]. It is well known that the recovery period after an acute exacerbation is long, even for patients with no subsequent exacerbations [40]. Thus, PR can be considered an effective intervention for reverting physical inactivity [41] and it has been shown that patients who achieved improvement in their daily physical activity level after an exacerbation of COPD experienced a ~ 50% reduction in risk of hospital readmission [42].

Health-related quality of life and exercise capacity

The primary result to support this, in the present review, are clinically relevant improvements in walking distance of respectively 76.89 m in 6 min walking distance (6MWD) and 54.70 m in shuttle walking distance (SWD) immediately after early PR and an improvement of 90.27 m in 6MWD at the longest follow up [43], which are in line with those results from Puhan et al. [14], showing an improvement of 62.38 m in 6MWD after early PR. Secondly, we found moderate quality of evidence supporting a clinically important improvement in HRQoL immediately after participation of 19.43 units on the SGRQ scale and an improvement of 8.74 units at the longest follow up. These effects on HRQoL exceeded the minimal clinically important difference (MCID) for the SGRQ (> 4-point improvement [44]), and the results are in line with previous studies showing a large effect of PR on HRQoL in stable patients with COPD [14]. Although statistically non-significant, the beneficial effects of early PR versus usual care on SGRQ at the longest follow up (8.74 units) in present review were close to those observed in stable COPD patients (6.89 units) [9]. In addition, the present review found a greater improvement in HRQoL at the end of treatment in patients with an exacerbation of COPD compared with stable COPD patients, which probably is due to the lower baseline during recovery from AECOPD.

Clinical application

We found no difference in drop-out rate between participants allocated to early PR compared with usual care. Thus, the effects were not driven solely by positive responders to PR, and secondly, the most severely affected patients will likely complete or drop-out to the same extent as usual care. As before mentioned, we did not include Greening et al. [17], since this study has been highly criticized for not offering a sufficiently extensive PR programs [45, 46], and interestingly, authors reported a high number of drop-outs. The participants in the rehabilitation group attended an average of 2.6 supervised sessions during hospital admission, followed by mainly unsupervised training after discharge, with a poor adherence to the home self-management exercise program (mean of 57.5) [17]. Nevertheless, these results suggest that it is important to assess how the PR is delivered. PR programs can differ in many aspects, which may influence their effectiveness. When assessing the extensiveness of the PR program; the number of exercise training sessions, frequency of exercise training, type of exercise training and supervision of training, as well as self-management, education and adherence to the PR program need to be considered [26].

In this review ten studies implemented an extensive PR program which mostly showed large and consistent effects on mortality, days in hospital, COPD related hospital readmissions, HRQoL, and walking distance. The PR programs were not exactly similar within the reviewed studies, but the majority provided either many training sessions (more than 16 sessions) [27, 29,30,31, 33, 34, 38], programs of long duration (> 12 weeks) [27, 38], or supported education [28, 30, 33, 35, 36]. Nevertheless, our results show that supervised early PR programs across studies with different protocols are effective in patients with COPD-related exacerbations.

Safety

Currently, the ideal timing of the onset of PR after AECOPD is highly debated. Based on low-quality of evidence, the ERS/ATS Task Force made a conditional recommendation against the initiation of PR during hospitalization since PR initiated during admission was found to increase mortality [18]. This conclusion seems based solely on results from Greening et al. [17], who reported a higher mortality in the unsupervised home-based rehabilitation group at 12 months compared with usual care group. The difference between groups however, was not related to the early rehabilitation intervention. Indeed, the per protocol analysis did not show a difference in mortality [17], suggesting that the participants who actually received the intervention were not accountable for the increased mortality [47]. We did not find any harms of early supervised PR across 13 RCTs, even when we isolated the subgroup that initiated PR during admission.

Conclusion

The results of the present review support the substantial and clinical important benefits of supervised early PR, indicating that this is an effective intervention with the purpose of reducing mortality following a hospitalization for AECOPD. Our meta-analysis shows that supervised PR during the recovery period after an AECOPD is superior to usual care in terms of improving prognosis, HRQoL and walking distance. Based on moderate to low quality of evidence, we conclude that supervised early PR reduces the risk of mortality, COPD-related hospital readmissions and the number of days in hospital, and lead to large and clinically relevant improvements in HRQoL and walking distance. Therefore, we recommend supervised PR to patients with COPD-related exacerbations. PR should be initiated during hospital admission or within 4 weeks after hospital discharge.